Listeria monocytogenes is a gram-positive bacteria and human pathogen widely used in cancer immunotherapy because of its capacity to induce a specific cytotoxic T cell response in tumours. This bacterial pathogen strongly induces innate and specific immunity with the potential to overcome tumour induced tolerance and weak immunogenicity. Here, we propose a Listeria based vaccination for melanoma based in its tropism for these tumour cells and its ability to transform in vitro and in vivo melanoma cells into matured and activated dendritic cells with competent microbicidal and antigen processing abilities. This Listeria based vaccination using low doses of the pathogen caused melanoma regression by apoptosis as well as bacterial clearance. Vaccination efficacy is LLO dependent and implies the reduction of LLO-specific CD4 + T cell responses, strong stimulation of innate pro-inflammatory immune cells and a prevalence of LLO-specific CD8 + T cells involved in tumour regression and Listeria elimination. These results support the use of low doses of pathogenic Listeria as safe melanoma therapeutic vaccines that do not require antibiotics for bacterial removal.
Introduction
Coley reported for the first time cancer therapies based on the use of bacteria after observation of the tumour regression in a patient after bacterial infection [1] . During the early development of bacterial-based anticancer therapies, different anaerobic bacteria were used that can proliferate in a hypoxic environment such as that of tumours. Some examples are Clostridium novyi, Bifidobacteria, Streptococcus pyogenes or Vibrio cholera. The use of bacteria as anticancer agents was followed by antibiotic treatment to control the infection. However, current bacterial-based anticancer therapies use attenuated strains of Salmonella and Listeria monocytogenes (LM) expressing specific antigens to target them to tumours and reduce tumour burden [2, 3] .
Listeria monocytogenes based vaccine vectors with attenuated strains show high efficiency against several tumours such as neuroglioma, hepatocellular carcinoma, cervical, prostate, and breast cancers, with a bacterial burden 500-fold higher than the classical doses used with pathogenic LM WT [4, 5] . The efficiency of Listeria based vaccines depends on the ability of the bacteria to induce a strong innate and T-cell based immunity playing an important role CD11c + dendritic cells (DCs) together with the pathogen's capacity to overcome tolerance to self-antigens such as tumour antigens [6] .
Melanomas are malignant forms of melanocytes and common skin cancers, with an incidence of 2%. They are particularly aggressive in highly photosensitive skin types. In our institution, the rate of incidence of melanoma increased by 3% in the last 2 years, becoming the most prevalent cancer among young women under the age of 40 years [7] . Melanoma is a low immunogenic tumour characterized by the aberrant expression of MHC class II molecules that might present melanoma-associated antigens to specific CD4 + T cells [8] . However, melanoma MHC class II expression correlates with metastatic disease and poor survival [9] and the melanoma specific CD4 + T cells appeared as tumour tolerogenic. Murine melanoma models that mimic the aggressive behaviour of metastatic melanoma, such as B16F10 cells, have been developed, and similar to humans, they also express MHC class II molecules [10] . Bacterial infection in melanoma or melanocytes has not been investigated in detail, and only rare infections have been reported such as non-tuberculosis Mycobacterium infection or abscesses of Salmonella enterica at the site of melanoma metastasis [11] [12] [13] . Several cases of cutaneous listeriosis in adults have also been reported; suggesting that infection of melanocytes with Listeria is possible [14] , although LM infection of melanoma or melanocytes is not well understood. Furthermore, most cases of neonatal listeriosis show diffuse skin lesions. Here, we hypothesized that Listeria tropism for melanoma might cause activation of the anti-melanoma immune response, blocking tumour progression. In the present study, we test this hypothesis performing a detailed analysis of the phagocytic abilities of melanoma cells after Listeria infection and propose a Listeria based vaccination for experimental melanoma.
Materials and Methods

Cells, recombinant proteins and peptides
Murine melanoma B16F10 cells were a gift from B. Alarcon and acquired from ATCC, human melanoma cell lines A-375 and Mel-H0, were a gift from M.D Boyano-Lopez and acquired from ATCC, J-774 murine macrophages and CHO cells were acquired from ATCC. Bone-marrow-derived dendritic cells (BMDC) were obtained from femurs of C57BL/6, Balb/c or CD-1 mice differentiated with 25 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) for 7 days as described [15] . Murine embryonic fibroblasts were cultured after thawing as previously described [16] . On day 7, we performed a positive selection of CD11c + -BMDC cells using magnetic beads and MACS separation columns (Miltenyi Biotech Inc., Auburn, CA) [15] . E. coli strain BL21 expressing large quantities of His-fusion recombinant LLO protein (LLO rec ) was provided by D.A. Portnoy. F. Roncal synthesized LLO [296] [297] [298] [299] [300] [301] [302] [303] [304] and LLO [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] peptides (CNB, CSIC, Madrid) followed by HPLC and Mass Spectrometry using a MALDI-TOF Reflex IV mass spectrometer (Bruker Daltonics, Bremen, Germany). Peptide purity was > 95% after HPLC. B16F10 cells (2 x 10 9 ) were homogenized as previously described for J-774 cells and precipitated with TCA and washed with PBS to obtain a B16F10 extract (MEL ext ) (1 mg/ml). [15] . J-774, MEF and CHO cells were infected as previously reported [16] . Colony forming units (CFU) were examined in blood agar plates and results are the mean ± SD.
Replication indexes of LM strains in melanoma and BMDC
Replication indexes (RIs) were calculated in CD11c + -BMDC, A-375, Mel-H0 and B16F10 cells infected as ratios of CFU at 16 h to CFU at 0 h ± SD of triplicates as reported [16, 17] . RI values higher than 25, represent a rapid LM proliferation and poor bactericidal abilities of the cells. Phagocytic rates corresponded to bacteria internalization rates at 0 h.
Phagosome isolation and cytosolic fractions
CD11c + -BMDC, A-375, Mel-H0 and B16F10 cells were infected for 1 hour and homogenized in HBE buffer (250 mM sucrose, 0.5 mM EGTA, 20 mM HEPES-KOH, pH 7.2) to obtain postnuclear supernatants (PNS). Phagosomes were isolated from an aliquot of PNS into a 20% sucrose gradient as described [16, 17] . An additional PNS was used to estimate the percentage of total internalized bacteria expressed as CFU. The percentages of phagosomal and cytosolic bacteria were calculated according to the following ratio, PNS-phagosomal numbers/PNS × 100, as described [16, 17] .
Phagosome western blotting and immunoprecipitations
Phagosomes isolated from BMDCs, B16F10, J-774, MEF or CHO cells infected with LM WT for 20 min, were solubilized and CFU analysed in blood agar plates. MHC-II and Rab5a molecules were detected by western blotting and the two forms of LLO bound to MHC class II molecules, LLO intact and processed LLO 1-491 forms were detected after immunoprecipitation with anti-MHC-II antibodies followed by western-blot with rabbit anti-LLO antibody as reported [17] .
Confocal microscopy
B16F10 and BMDC cells were infected with GFP-LM for 1 h, washed, fixed in 3% paraformaldehyde and permeabilized with PBS-0.05% Triton X-100 as reported [15] [16] [17] . Confocal microscopy imaging was performed with a Nikon A1R confocal microscope.
B16F10 induction of carcinomatous peritonitis and LM vaccination
C57BL/6 female mice (n = 5) were inoculated in the peritoneal cavity (i.p) with 5 × 10 5 B16F10 cells for 7, 15 or 23 days. For LM WT vaccinations, mice inoculated i.p with B16F10 for 7 days were next infected i.p with 5 × 10 3 GFP-LM (CFU/mice) (n = 5) for 5 days to analyse LM innate and specific immunity. Mice were bled before sacrifice and sera stored at −80°C to measure cytokines by FACS analysis. Spleens, peritoneal melanoma and lungs were recovered and photographed. Spleens and melanoma were further processed for FACS analysis and an aliquot plated into blood-agar plates to count CFU.
Immunohistochemistry
Mice were sacrificed on days 7, 15 and 23 after melanoma inoculation. The most common metastatic organs (liver, spleen, kidney, adrenal glands, liver and lungs) were resected, sectioned, and fixed by immersion in 4% formaldehyde for 24 h. Organs were subsequently embedded in paraffin and cut at 3-μm thickness for histological analysis. Different sections (stained with hematoxylin-eosin) of each organ were analysed by two independent pathologists. For immunohistochemical analysis of lymphocyte markers, EnVision technology (Dako) was used. Samples were boiled in target retrieval solution buffer (pH 6 for CD23, pH 8 for the rest) for 20 min, subsequently cooled in distilled water and 1×PBS. ) or spleens and recovered melanoma from mice treated with B16F10 and infected with the above mentioned LM strains were analysed by FACS for the following markers: CD4-PE, CD8α-PE, CD49b-PE, F4/80-PE, CD11b-APC, CD11c-PE, MHC-II-APC, CD40-PE, CD83-APC, CD86-V450 and iNOS/type II-FITC. Melanoma cells from mice were also analysed for apoptosis by FACS analysis using Annexin-V-APC and 7-AAD (BD-Biosciences). Mice sera or supernatants of B16F10 cells infected or not with LM WT for 24 hours were used to quantify cytokines using the CBA kit (Becton Dickinson, Palo
Alto, CA, USA). Samples were analysed in triplicate and results were expressed as the mean ± SD of two separate experiments. For measuring of intracellular IFN-γ, spleen cells were cultured in 96-well plates (5 x 10 6 cells/ml) and stimulated with recombinant LLO (0.1 μg/ml), B16F10 extract (50 μg/ml) (MEL ext ), LLO 190-201 (50 μM) or LLO 296-304 peptides (50 μM) for 5 h in the presence of brefeldin A [15, 17] . Next, cells were surface labelled for CD4 or CD8, fixed and permeabilized with cytofix/cytoperm kit to measure intracellular IFN-gamma (BD Biosciences). After sample acquisition, data were gated for CD4 + or CD8 + events, and the percentages of these cells expressing IFN-gamma were determined according with the manufacturer's recommendations. Results were corrected according to the percentages of total CD4 + or CD8 + positive cells.
Data were analysed using FlowJo software (Treetar, Ashland, OR).
Frequencies of LLO-peptide specific CD8 + T cells
To confirm the frequency of LLO 296-3049 -specific CD8 T cells producing IFN-gamma, we used recombinant soluble dimeric mouse H-2K b :Ig fusion protein following the instructions of the manufacturer (DimerX I; BD Bioscience). LLO 296-304 peptide (40 μM) was pre-incubated with PE-conjugated H-2K b :Ig (1 μM) in PBS, at 37°C for 16 h as previously described [15] . Splenocytes (2 × 10 7 cells/ml) were incubated with IFN-gamma and CD8 antibodies and the staining cocktail mix described above for 10 min at 4°C. Percentages of CD8 + gated cells were expressed as the mean ± SD of triplicates (P < 0.05). Data were analysed using FlowJo software.
Measurement of NO production
B16F10 and BM-DC were infected with LM or not and assayed for NO production as previously reported [18] .
B16F10 subcutaneous tumour model and LM vaccination
Newborn C57BL/6, Balb/c or CD-1 mice of 2 days old (n = 10) were inoculated in the back subcutaneously (s. 
Statistical analysis
Student's t test was used for statistical analysis and analysis of variance (ANOVA) for cytokine measurements. Data were analysed using FlowJo software (Treestar, Ashland, OR). P 0.05 was considered significant. GraphPad software was used for graphic presentation. 
Ethics statement
Results and Discussion
Coley's observations that a neck cancer patient recovered after infection with erysipelas initiated the use of bacteria and their toxins to treat end stage cancers [3] . However, pathogenicity and toxicity are important concerns limiting the broad clinical application of bacteria as anticancer agents. In this regard, the adjuvant features of LM involve its ability to target and activate DCs and its dual intracellular distribution in phagosomes and cytosol, which allows the activation of LM specific CD4 + and CD8 + T cells. However, two additional LM characteristics seemed also relevant to target tumour cells [5] and to live under hypoxic conditions. Attenuated LM strains on a truncated form of listeriolysin O (LLO) fused to tumour antigens appeared as promising vaccines for cervical and breast cancer [4, 5] . These cancer vaccines exerted their effect through out the killing of tumour cells by CD8 + cytotoxic responses to tumour antigens.
However, there are other mechanisms by which Listeria-based cancer vaccines show their actions, independent of tumour antigens. Here, we present a dramatic effect of LM WT vaccination
on an experimental melanoma model with poor immunogenicity, the B16F10 induction of cancerous peritonitis. We provide evidence of melanoma growth reduction after LM WT vaccination and transformation of tumour cells into activated dendritic cell phenotypes that activates Listeria-specific CD8 T cell responses and innate pro-inflammatory responses that in turns eliminated the pathogen.
In vitro Listeria induced transformation of melanoma into dendritic cells
Melanoma is one of the fastest growing cancers in the world, and surgery is the best available therapy for this malignancy both during the early developmental stages and in advanced metastatic melanoma. Therefore, alternative measures are needed as the one proposed in this study using low doses of pathogenic LM WT as a vaccination therapy. This therapy is based in the high tropism of LM for melanoma [5, 19] and the transformation of these tumour cells into dendritic-like cell phenotypes functioning as competent APC. We first observed that murine or human melanoma cell lines infected with pathogenic LM WT , transformed these malignant melanocytes into professional antigen presenting cells, On the other side, non-APC cell types such as mouse embryonic fibroblasts (MEF) or the ovarian CHO tumour cells lacked listericidal abilities since both LM WT and LM ΔLLO showed exponential intracellular growth as previously reported [16] (S1A Fig.) . These results strongly suggested that melanoma function as professional phagocytes. Next, we verified APC function examining the antigen processing compartments (MIIC) competency. Melanoma cells infected with LM WT , showed phagosomal-like structures with significant co-localization of green-fluorescent bacteria, GFP-LM WT and MHC-II molecules (yellow fluorescence in Fig. 1C ), reflecting high MIIC competency. Similarly, purified phagosomes of melanoma and BMDC presented high levels of classical MIIC markers [16, 17] such as the endosomal-phagosomal regulator Rab5a, stable a/b MHC-II molecules and significant amounts of LLO processed forms that bound to MHC class II molecules (western blots in Fig. 1C and S1B Fig.) . They also presented lysosomal enzymes involved in LLO processing such as cathepsin-D (S1B Fig.) and low CFU values confirming their microbicidal capacities (CFU Phago values below western blots of Fig. 1C ) [16] [17] [18] . J-774 macrophages presented almost all MIIC markers except for low levels of cathepsin-D, while non-APC cells as MEF or CHO exclusively showed the MIIC marker Rab5a, indicating very low MIIC competency (S1B Fig.) Fig. 1D and Table 1 ). This melanoma transformation required LLO since LM ΔLLO mutants caused no change in the phenotype (grey bars in Fig. 1D ). The strategy was as follows; first we selected on the FACS plots of non-infected melanoma (B16F10-NI in Fig. 1D -FACS plots on right), the single positive MHC-II cells. Using same parameters, we selected on FACS plots of melanoma-infected cells (B16F10-LMWT in Fig. 1D -FACS plots on the right), the single positive MHC-II cells. Next, we selected the double positive MHC-II and CD11c or CD40 or CD83 or CD86 cells (last arrow sequence in B16F10-LMWT plots in Fig. 1D -FCAS plots on the right). Infection of human melanoma A375 and Mel-H0 with LM WT also shifted the phenotype towards an activated DC-like phenotype characterized [15] . LM WT infection of other APC such as J-774 macrophages does not cause transformation into DC-like phenotypes (S1 Fig., panel C) , either production of the pro-inflammatory cytokines above-mentioned [15, 17] . In brief, LM WT infection transformed melanoma into matured DC with competent APC functions and potential for tumour therapies.
Listeria therapy of melanoma causes tumour regression by apoptosis and bacterial clearance
To evaluate the potential of a LM WT based therapy for melanoma, we set up a model of carcinomatous peritonitis induced by inoculation of B16F10 melanoma into C57BL/6 mice peritoneum for different times, 7, 15 or 23 days. The progression of melanoma in this model was as follows, after 7 days of melanoma inoculation, there is an infiltrate of tumour cells in the Table 1 . Listeria infection of melanoma induces nitric oxide and iNOS expression. peritoneum (dark staining in peritoneum images of Fig. 2A ) and melanoma colonization of the white fat of peritoneal organs with no infiltration on the green fat (white fat images of Fig. 2A) values) (Fig. 2B) . However, the significant growth of melanoma in the peritoneum after 7 days, predicted that melanoma induced T cell responses were not tumoricidal but melanoma tolerant. In fact, after 15 days, there is an exaggerated melanoma growth in the peritoneum and metastases in lungs and livers (liver metastasis images of Fig. 2A ). The immune responses become ) for 5 additional days. Mice were sacrificed, bled to collect sera and photographed before collecting melanoma and lungs. Images correspond to the peritoneum of mice and the recovered melanoma. Plots correspond to measurements of diameters of collected melanoma. Results are expressed as the mean ± SD (P < 0,05). D, Melanoma recovered from LM WT or LM ΔLLO vaccinated mice or from non-vaccinated mice (NV) as in C were analysed for early and late apoptosis by FACS according to Materials and Methods after double staining with 7-AAD (IP labelled) and annexin V (anexina labelled). Results are expressed as the percentages of late apoptotic cells, necrotic death, (Q2 area corresponding to double positive for 7-AAD and annexin V cells) and the percentages of early apoptotic cells, programmed cell death (Q4 area corresponding to annexin V positive while 7-AAD negative cells) (mean ± SD) (p < 0.05). down regulated after 15 days (15-D images of Fig. 2B ) and melanoma tolerance allowed tumour growth without control and the death of most of the mice after 23 days. Since bacterial vaccinations required at least 5 days for developing optimal innate and specific immune responses, we chose 7 days of melanoma induction to initiate the bacterial therapies, assuring maximal physiological conditions of the mice. LM WT therapy of melanoma using low doses of the pathogen (5 x 10 3 CFU/mice) caused 10-fold reductions on the melanoma size after 5 days post-challenged (LM WT bars in Fig. 2C ).
LLO is required for melanoma regression since therapies with LM ΔLLO strains caused no effect on the melanoma size (LM ΔLLO bars in Fig. 2C ). Subcutaneous (s.c) inoculation of melanoma into new-born pups followed by LM WT therapy (s.c) also reduced 6-fold the tumour size in different mice strains (S2 Fig., panel A and B) . These results suggested that melanoma regression seemed to occur also in the skin of immune tolerant post-natal mice of different gene backgrounds. In the peritoneal carcinomatous B16F10 induced model, we also observed that reduction of the tumour size correlated with 10-fold reduction of melanoma adherence and mitotic indexes (Table 2) , indicating alterations on their cell cycle due to apoptosis or necrotic death.
To differentiate both types of death, we examined early and late apoptosis ratios in recovered melanoma after vaccination with LM WT , LM ΔLLO or no vaccination (NV). Direct LM WT infection of melanoma caused no change in late or early apoptosis in melanoma controls (CON-TROL B16F10-NT plots of Fig. 2D ). An increase in late apoptosis would correspond to necrotic death, while increases in early apoptosis ratios would indicate programmed cell death by stimuli such as cytokines. Melanoma recovered from LM WT vaccinated mice showed 2-fold increases on early apoptosis, indicating that melanoma eradication occurred by programmed cell death and not by necrotic death (MEL-recovered LM WT plots of Fig. 2D ). Non-vaccinated mice or LM ΔLLO vaccinated showed no effect in melanoma cell cycle (MEL-recovered NV and MEL-recovered LM ΔLLO plots of Fig. 2D ). Tumour regression also correlated with high LM WT tropism for melanoma as we localized 45% of LM WT vaccination in the recovered melanoma (legend in section d of Table 2 ). These results indicated that melanoma regression required LM phagocytosis by tumour cells. Therefore, we next examined the different phagocytic and APC capacities of the recovered melanoma. We observed 3-fold increases in the microbicidal abilities of the recovered melanoma after LM WT vaccination since LM WT phagocytic rates and replication indexes decreased (LM WT -MEL in Table 2 ). We also detected an increase in the APC competences since examination of cell surface markers verified that LM WT vaccination of melanoma shifted the matured DC phenotype to a fully activated DC pattern in the recovered melanoma (LMWT-MEL under APC markers column of 
T cells using recombinant LLO or peptides
To explore the immune responses generated by melanoma therapy with LM WT , we examined the cell populations in the spleens of mice with LM WT therapy (black bars in Fig. 3A) . First, we observed that 96% of the inoculated LM WT localized in MHC-II + cells, 56% CD11c + DCs and 40% CD11b + macrophages (GFP-LM black bars in Fig. 3A) . These percentages were similar to the cell populations observed in classical LM WT infections (GFP-LM grey bars in Fig. 3A) . suggesting that T cells were Listeria driven (Fig. 3A) . We next examined LLO specific T cell responses induced by melanoma therapy with LM WT since LLO seemed relevant in this melanoma model and in most reported Listeria-based immune-therapies [4, 5, 15, 24] . Therapy of melanoma with LM WT stimulated higher 1.79 ± 0.03 percentages of recombinant LLO (LLO rec )-specific CD8 + cells and IFN-gamma producers and lower 0.4 ± 0.01 percentages of Listeria Vaccination Causes Melanoma Regression LLO rec -specific CD4 + cells and IFN-gamma producers (Fig. 3C) . While a classical LM infection after 5 days produced similar percentages of LLO 190-201 specific CD4 + and LLO 296-304 specific CD8 + T cell subsets and IFN-gamma producers, 1.05 ± 0.02 and 1.02 ± 0.01 percentages, . Cells were stimulated 5 h with recombinant LLO (0.1 μg/ml) in the presence of brefeldin A for intracellular cytokine staining. LLO-stimulated spleen cell surface was stained for CD4 or CD8 and fixed and permeabilized using cytofix/cytoperm kit. Stimulated cells were surface stained for CD4 or CD8 using anti-CD4 + FITClabeled or anti-CD8 + APC-labelled and data gated to include histograms show the percentages of LLO-CD4 + and IFN-gamma producers (lower left) and LLO-CD8 + and IFN-gamma producers (lower right) (R2 and R3 gates). Experiments were performed in triplicate and results are expressed as the mean ± SD (p < 0.05). D, Spleen cells obtained from homogenates after inoculation with melanoma B16F10 pre-infected with LM WT (5 x 10 5 cells/mice) for 7 days. Cells were stimulated 5 h with recombinant LLO (0.1 μg/ml) in the presence of brefeldin A for intracellular cytokine staining. Procedures were performed as in C and results expressed as the mean ± SD (p < 0.05). respectively (S3 Fig., panel A) . Increased cytotoxic T cell responses seemed to explain the accelerate LM WT clearance in the spleens (LM growth plot in Fig. 3A) . These results strongly sug- T cells producing IFN-gamma (Fig. 3C) . We also observed decreased 0.03 ± 0.01 percentages of LLO 190-201 specific CD4 + and enhanced 1.76 ± 0.03 percentages of LLO 296-304 specific CD8 + T cells producing IFN-gamma (S3 Fig., panel B) . We also evaluated immune responses to melanoma antigens using a B16F10 extract (MEL ext Table 3 ). The increase in LLO specific CD8 + T cell responses, correlated with regression of melanoma size observed in mice inoculated with melanoma pre-infected with LM WT or control melanoma (S3 Fig., panel D) . This is a widely common mechanism of several pathogenic bacteria used in cancer therapies [1, 4, 25] . In fact, other Listeria-based vaccines against breast cancer function by similar mechanisms [5] . In conclusion, we envision the following model (Fig. 4) to explain the efficiency of our LM WT vaccination. After the melanoma model is established in the mice for 7 days (step 1), vaccination with low doses of pathogenic LM WT for 5 days (step 2) accessed the growing tumour and infected these cells (step 3). LM WT infection of melanoma transformed them into matured dendritic-like cells (MEL-DCm) (step 4) with APC competence and MIIC phagosomes that degraded LLO to LLO processed forms LLO that allowed the generation of LLO restricted CD4 + T cells and LLO restricted CD8 T cells. This Listeria-driven melanoma transformation also generates exaggerated levels of the pro-inflammatory cytokines/chemokines, MCP-1, TNF-α and IL-12 and high production of nitric oxide (NO), a well known listericidal and tumour reducer molecule (step 5) [18] . This LM-driven melanoma transformation also amplifies the activation of LLO 296-304 restricted CD8 + T cells (step 5) and blocks the stimulation of LLO 190-201 restricted CD4 + T cells (step 5) [28] . The exaggerated levels of pro- + -restricted T cells would cause a LLO-driven tumour destruction by programmed cell death (step 6). Also these LLO 91-99 /CD8 + -restricted T cells producing high levels of IFNgamma would activate the LM WT infected melanoma (MEL-Dm) to a fully activated state (MEL-DCma) that might eliminate the pathogen (step 6) with the advantage of not requiring antibiotic treatment to destroy this low dose of the pathogen used as therapeutic vaccine. Here we proposed that targeting of Listeria to melanoma and transforming melanoma into dendritic cells is a new mechanism of vaccine efficacy that can be applied to attenuated Listeria vaccines expressing tumour antigens proposed currently as therapies [19, 31] .
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